WASHINGTON (dpa-AFX) - Seattle Genetics, Inc. (SGEN) Tuesday said it received a non-conditional marketing authorization from Health Canada for its Adcetris as post-autologous stem cell transplant consolidation treatment of patients with Hodgkin lymphoma at increased risk of relapse or progression. The indication was based on positive results from the phase 3 Aethera clinical trial.
Adcetris is not currently approved for use in frontline Hodgkin lymphoma.
Copyright RTT News/dpa-AFX